Clene Inc. (CLNN)

Market Cap	32.64M
Revenue (ttm)	421,000
Net Income (ttm)	-36.02M
Shares Out	7.98M
EPS (ttm)	-5.58
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	127,030
Open	4.660
Previous Close	4.660
Day's Range	3.880 - 4.770
52-Week Range	3.820 - 12.000
Beta	0.41
Analysts	Strong Buy
Price Target	59.25 (+1,348.66%)
Earnings Date	Nov 13, 2024

About CLNN

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 ...

• Industry: Packaged Foods
• Sector: Consumer Staples
• Founded: 2012
• Employees: 85
• Stock Exchange: NASDAQ
• Ticker Symbol: CLNN
• Website: https://clene.com

Financial Performance

In 2023, Clene's revenue was $654,000, an increase of 38.27% compared to the previous year's $473,000. Losses were -$49.50 million, 65.5% more than in 2022.

Analyst Forecast

According to 4 analysts, the average rating for CLNN stock is "Strong Buy." The 12-month stock price forecast is $59.25, which is an increase of 1,348.66% from the latest price.

Price Target

$59.25

(1,348.66% upside)

Analyst Consensus: Strong Buy